Royal Devon University Healthcare NHS Foundation Trust

Biologic Medicines Usage In Dermatology

Reference Number: F4924
Date of Response: 02/11/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

Q1. How many patients were treated in the last 3 months by the **Dermatology** department (for any medical condition) with the following biologic drugs:

- Abatacept
- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Golimumab
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Tofacitinib
- Ustekinumab
- Upadacitinib

Q2. How many patients were treated in the last 3 months by the **Dermatology** department for Psoriatic Arthritis (PsA) ONLY with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Certolizumab
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade

- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Ustekinumab

The Trust has looked into your request for information. The Trust systems do not currently have a standardised dataset for to access on dispensed drugs, to enable the Trust to answer the questions for this FOI . The Drugs and how they are dispensed via clinics is not information always held on Trust systems. Information is not routinely recorded in the formats readily accessible. Time and resources would be required to provide the requested information in your questions 1 and 2, and this would exceed the limit envisaged under the Act. The Freedom of Information Act does not oblige a public authority to create information to answer a FOIA. The duty under FOI is to only provide the recorded information held.

Therefore, the Trust applies the Section 12 exemption under the Freedom of Information Act 2000 to these questions.